Quantifying Inequities in COVID-19 Vaccine Distribution Over Time by social vulnerability, race and ethnicity, and location: A Population-Level Analysis in St. Louis and Kansas City, Missouri

5 Authors:

Aaloke Mody, M.D.¹; Cory Bradley, Ph.D.¹; Salil Redkar, M.S.¹; Branson Fox, B.A.¹; Ingrid EshunWilson, MB.ChB., M.Sc.¹; Matifadza G. Hlatshwayo, M.D., M.P.H.²; Anne Trolard, M.P.H.^{1,3}, Khai
Hoan Tram, M.D.⁴; Lindsey M. Filiatreau, Ph.D.¹; Franda Thomas, M.Ed.²; Matt Haslam, M.Sc.²;
George Turabelidze, M.D., Ph.D.⁵; Vetta Sanders-Thompson, Ph.D.⁶; William G. Powderly, M.D.^{1,3};
Elvin H. Geng, M.D., M.P.H.^{1,3}

11 12

4

- 13 1 Washington University School of Medicine, St. Louis, Missouri, USA
- 14 2 St. Louis City Department of Health, St. Louis, Missouri, USA
- 15 3 Institute for Public Health, Washington University in St. Louis, St. Louis, Missouri, USA
- 16 4 University of Washington School of Medicine, Seattle, WA, USA
- 17 5 Missouri Department of Health and Senior Services, Jefferson City and St Louis, Missouri, USA
- 18 6 Brown School of Social Work, Washington University in St. Louis, St. Louis, Missouri, USA

19 20

Keywords: COVID-19 vaccinations; Racial Disparities; Lorenz Curve; Inequity; structural racism; vaccine locations; social vulnerability index

23 24

25

26 **Corresponding Author:**

- 27 Aaloke Mody, M.D.
- 28 Division of Infectious Diseases
- 29 Department of Medicine
- 30 Washington University School of Medicine
- 31 Campus Box 8051, 4523 Clayton Avenue
- 32 St. Louis, MO 63110
- 33 Phone: 314-454-8293
- 34 Fax: 314-454-5392
- 35 Email: <u>aaloke.mody@wustl.edu</u>
- 36 37

38 ABSTRACT

39

BACKGROUND: Equity in vaccination coverage is a cornerstone to a successful public health
 response to COVID-19. To deepen understand of the extent to which vaccination coverage compared
 to initial strategies for equitable vaccination, we explore primary vaccine series and booster rollout
 over time and by race/ethnicity, social vulnerability, and geography.

METHODS AND FINDINGS: We analyzed data from the Missouri State Department of Health and 44 Senior Services on all COVID-19 vaccinations administered across 7 counties in the St. Louis region 45 and 4 counties in the Kansas City Region. We compared rates of receiving the primary COVID-19 46 vaccine series and boosters relative to time, race/ethnicity, zip code-level social vulnerability index 47 48 (SVI), vaccine location type, and COVID-19 disease burden. We adapted a well-established tool for measuring inequity-the Lorenz curve-to quantify inequities in COVID-19 vaccination relative to 49 these key metrics. Between 12/15/2020 and 2/15/2022, 1,762,508 individuals completed the primary 50 series and 871,896 had received a booster. During early phases of the primary series rollout, Black 51 and Hispanic individuals from high SVI zip codes were vaccinated at less than half the rate of White 52 53 individuals, but rates increased over time until they were higher than rates in White individuals after 54 June 2021; Asian individuals maintained high levels of vaccination throughout. Increasing vaccination 55 rates in Black and Hispanic communities corresponded with periods when more vaccinations were 56 offered at small community-based sites such as pharmacies rather than larger health systems and 57 mass vaccination sites. Using Lorenz curves, zip codes in the guartile with the lowest rates of primary series completion accounted for 19.3%, 18.1%, 10.8%, and 8.8% of vaccinations but represented 58 25% of either the total population, cases, deaths, or population-level SVI, respectively. When tracking 59 Gini coefficients, these disparities were greatest earlier during rollout, but improvements were slow 60 and modest and vaccine disparities remained across all metrics even after one year. Patterns of 61 62 disparities for boosters were similar but often of much greater magnitude during rollout in Fall 2021. Study limitations include inherent limitations in vaccine registry dataset such as missing and 63 misclassified race/ethnicity and zip code variables and potential changes in zip code population sizes 64 65 since census enumeration.

CONCLUSIONS: Racial inequity in the initial COVID-19 vaccination and booster rollout in two large 66 U.S. metropolitan areas were apparent across racial/ethnic communities, across levels of social 67 vulnerability, over time, and across types of vaccination administration sites. Disparities in receipt of 68 69 the primary vaccine series attenuated over time during a period in which sites of vaccination administration diversified, but were recapitulated during booster rollout. These findings highlight how 70 71 public health strategies from the outset must directly target these deeply embedded structural and 72 systemic determinants of disparities and track equity metrics over time to avoid perpetuating 73 inequities in health care access.

74 AUTHOR SUMMARY75

80

90

92

99

105

111

115

120

76 Why Was This Study Done? 77

- Equitable vaccine strategies are critical for the public health response to COVID-19, but there is limited understanding of how vaccination campaigns compared to different metrics for equity.
- Many initial approaches to vaccine allocation sought to acknowledge the known disparities in exposure
 risk, disease burden, needs, and access by formally considering social vulnerability or race/ethnicity in
 plans to prioritize vaccinations, but there is limited empirical evaluation of how actual primary vaccine
 series and subsequent booster efforts aligned with the initial goals set out for equity.
- We quantify COVID-19 vaccine-related inequities in receipt of the primary vaccine series and booster
 across key equity metrics including race/ethnicity, social vulnerability, location, and time using a novel
 application of Lorenz curves and Gini coefficients—tools from economics to measure inequalities—in the
 St. Louis and Kansas City regions of Missouri.

91 What Did the Researchers Do and Find?

- We analyzed data from the Missouri State Department of Health and Senior Services on all COVID-19
 vaccinations administered in the St. Louis region and Kansas City Regions. We compared rates of
 receiving the primary COVID-19 vaccine series and boosters relative to time, race/ethnicity, zip code-level
 social vulnerability index (SVI), vaccine location type, and COVID-19 disease burden. We adapted Lorenz
 curves and Gini coefficients to quantify the inequities in COVID-19 vaccination relative to these key metrics
 and examined how they changed over time.
- Black and Hispanic individuals from high SVI zip codes completed the primary series at less than half the rate of White individuals during early phases of the primary series rollout, but surpassed rates in White individuals after June 2021. These relative increases in primary series completion rates in Black and Hispanic communities corresponded to periods when vaccinations became more available at small community-based sites.
- Lorenz curves demonstrated that zip codes in the quartile with the lowest rates of primary series completion accounted for 19.3%, 18.1%, 10.8%, and 8.8% of vaccinations but represented 25% of either the total population, cases, deaths, or population-level SVI, respectively. Tracking Gini coefficients over time demonstrated that these disparities were greatest earlier during rollout, but only improved slowly and modestly over time.
- Patterns of disparities for boosters were similar but often of much greater magnitude that those seen with
 completion of the primary vaccine series. patterns of disparities were similar but often of greater magnitude
 during booster rollout in Fall 2021.

116 What Do These Findings Mean? 117

- Vaccination coverage for both the primary series and boosters demonstrated substantial disparities across
 race/ethnicity, levels of social vulnerability, types of vaccine administration sites, and over time.
- Despite well-documented inequities for COVID-19 and need for equitable vaccine approaches, the
 strategies employed did not overcome deeply entrenched systemic inequities in health care and society.
- Public health strategies must proactively target these deeply embedded structural determinants of
 disparities from the outset and should systematically track equity metrics over time to avoid perpetuating
 inequities in health care access.

127 INTRODUCTION

The initial wave of coronavirus disease 2019 (COVID-19) redemonstrated and highlighted 128 historical inequities in health by race, ethnicity, and other social indicators of vulnerability [1-3], 129 prompting a range of efforts to design public health services that redress inequity in the COVID-19 130 response. Across a wide range of indicators, disease burden as measured by COVID-19 cases, 131 hospitalizations, and mortality has disproportionately affected minoritized communities [1-3]. Initial 132 responses to COVID-19 through established channels were thus accompanied by additional efforts to 133 address the evolving disparities. Nevertheless, minoritized and vulnerable communities still had 134 reduced access to testing and treatments and have endured disproportionate impacts of social 135 distancing and lockdown policies on employment, education, and housing [4-8]. Against this 136 backdrop, achieving equitable vaccinations has and continues to be one of the most critical public 137 health challenges for mitigating the impact of the COVID-19 pandemic and achieving long-term 138 control. 139

Closer examination of equity in the vaccine response evaluating the extent to which health 140 systems performed in this domain is still necessary, and something that has not clearly documented 141 in the literature to date. Whereas equality simply refers to provision of equal resources to every 142 individual regardless of need, equitable approaches acknowledge that individuals will have different 143 risks, needs, or opportunities and that access to or distribution of resources needs to take these 144 differences into account. Strategies and frameworks to guide the equitable allocation and distributions 145 of vaccine were developed for when vaccines for SARS CoV-2 became available in December 2020 146 [9,10], but empirical examination of how actual primary vaccine series and subsequent booster efforts 147 aligned with the initial goals set out for equity are still needed. For example, several strategies 148 proposed formally considering geography, social vulnerability, or race/ethnicity in plans to prioritize 149 and distribute vaccinations in response to the known inequities in exposure risk and disease burden 150 across these metrics [11-13]. Examinations of equity must thus document patterns of vaccinations 151

- across race/ethnicity, social vulnerability, geography, over time, and how they are delivered to
- understand the mechanisms that give rise to disparities and yield key insights to the success, failures,
- and steps for redress to achieve equitable vaccination strategies.
- In this manuscript, we deepen our understanding of COVID-19 vaccine-related disparities by 155 examining inequities in vaccination in the St. Louis and Kansas City regions in Missouri-regions with 156 a history of health disparities—across several key metrics. We characterize rates of receiving the 157 primary vaccine series and boosters over time, race/ethnicity, social vulnerability, disease burden, 158 geography, and across vaccination location types. We use Lorenz curves and Gini coefficients-tools 159 from economics commonly used to measure inequity in a population-to guantify and track inequities 160 in COVID-19 vaccination over time relative to different metrics for conceptualizing equity [14]. The 161 novel application of this methodology-which we previously used to characterize COVID-19 testing 162 disparities [4]—has potential to yield deeper insights into the progress made towards vaccine equity 163 in these regions that may then better inform health policy solutions to address remaining gaps. 164
- 165

166 METHODS

167 Ethics statement

The study was approved by the institutional review board at Washington University in St. Louis (IRB ID# 202009021). The research in this paper was not pre-specified and consists of secondary analysis of preexisting de-identified data. This manuscript was prepared according to STROBE guidelines (S1 STROBE Checklist).

172

173 Study Setting and Data

We sought to assess disparities in COVID-19 vaccination across the 7 counties in the St. Louis 174 region (St. Louis City, St. Louis County, St. Charles, Jefferson, Franklin, Lincoln, and Warren; total 175 population 2.095.978; 19.2% Black, 73.1% White, 3.0% Hispanic, 3.2% Asian) and the 4 counties in 176 the Kansas City region (Jackson, Clay, Cass, and Platte; total population 1,121,224: 16.8% Black, 177 73.2% White, 8.2% Hispanic, 2.0% Asian). These counties make up the broader metropolitan area 178 located within Missouri for these two cities. Vaccines first became available on December 15, 2020 179 and all individuals became eligible on March 29, 2021. We used data from the Missouri State 180 Department of Health and Senior Services on SARS-CoV-2 vaccines administered in Missouri to 181 individuals 12 years old and up between December 15, 2020 and February 15, 2022. Reporting for 182 vaccinations was mandated so this database is expected to contain near complete data on all 183 184 vaccinations administered in Missouri. This individual-level dataset contains vaccination date, type, and dose number; administration site; and patient age, sex, race/ethnicity, and zip code, and was de-185 duplicated and cleaned by the Missouri State Department of Health and Senior Services. We used 186 2020 census data to obtain age-, sex-, and race-stratified zip code population estimates and 2018 187 American Community Surveys (ACS) data to obtain sociodemographic and socioeconomic 188 characteristics of individual zip codes as well as the CDC's social vulnerability index (SVI). The SVI is 189 a composite metric that captures a community's vulnerability to external stresses on human health 190 and is calculated from 15 ACS variables measuring demographics, socioeconomic status, household 191 composition, and infrastructure [15]. 192

193 Analyses

Our analyses seek to characterize patterns of disparities in receiving the primary vaccine series and boosters over time by examining rates of vaccination with respect to race/ethnicity and social vulnerability, changes in the type of locations vaccines were being administered, and the extent to which vaccine administration was equitable between zip codes. We adapted methods that we had

previously used to assess disparities related to COVID-19 testing and extend them to COVID-19
 vaccination [4].

First, we estimated the rates and cumulative incidence of COVID-19 vaccinations over time 200stratifying individuals by race/ethnicity (i.e., Black, White, Hispanic, or Asian) and whether they lived 201 in zip codes with a low, medium, or high SVI (i.e., less than 0.333, 0.333 to 0.666, or greater than 202 0.666, respectively). We examined completion rates for the primary vaccine series (defined as 2 203 doses of either BNT162b2 mRNA [Pfizer] or mRNA-1273 [Moderna] or a single dose of Ad26.COV2.S 204 [Johnson and Johnson]) and boosters (defined as a single dose of any vaccine after completing the 205 primary series). Second, we examined the distribution by the type of sites at which individuals were 206receiving their primary vaccine series and boosters over time and by race/ethnicity and zip code-level 207 SVI. We categorized vaccine administration sites into health facilities (e.g., clinics, hospitals, health 208 system-affiliated sites) that administered either a small, medium, or large volume of vaccinations (i.e., 209 less than 1000, 1000 to 10,000, or greater than 10,000 unique individuals vaccinated, respectively), 210 public health departments (including mass vaccination sites), pharmacies, employer/school-based 211 212 sites, and other (e.g., dialysis centers, home health, nursing homes, mental health/psychiatric facilities, and correctional facilities). 213

Third, we generated modified versions of Lorenz curves to assess the relative equity in the 214 distribution of COVID-19 vaccinations across zip codes. Lorenz curves-originally developed by 215 216 economists to graphically represent income equality-have more recently been leveraged as a tool for public health [14,16,17]. Lorenz curves are generated by plotting the cumulative proportion of the 217 total population against the cumulative proportion of a resource after sorting values in ascending 218 219 order. The curve follows a straight line at a 45-degree angle when a resource is equitably distributed across the population and becomes more convex with increasing inequity. In general, equitable 220 vaccination strategies would seek to balance the number of vaccines with the overall risk of disease 221 222 in a community, but the most appropriate metric of equity for so doing will depend on whether one

considers the goal to be creating balance between vaccination rates relative to the total population. 223 overall disease burden (i.e., number of COVID-19 cases or deaths), or risk factors (i.e., social 224 vulnerability) in a community. To examine vaccine equity from these different perspectives, we 225 adapted the Lorenz curve method to examine disparities in receiving the primary vaccine series and 226 boosters relative to several relevant metrics: 1) the total population, 2) number of diagnosed COVID-227 19 cases, 3) number of COVID-19 deaths, and 4) population-level social vulnerability, which we 228 defined as the zip code-level social vulnerability index multiplied by its population. For each curve, we 229 calculated Gini coefficients—a measure of equality/inequality between 0 and 1, with 0 indicating 230 perfect equality and 1 indicating perfect inequality—and assessed how these changed over time [18]. 231 We also grouped zip codes into guartiles based on their position on Lorenz curves and assessed 232 differences in zip code-level sociodemographic and socioeconomic characteristics using Kruskal-233 Wallis tests. 234

Fourth, we generated bubble plots to compare primary vaccine series and booster completion rates for Black, Hispanic, and Asian residents relative to White residents living in the same zip code. For these analyses, we only considered zip codes whose populations had at least 25 individuals for each of the race/ethnic groups being compared to avoid extreme outliers from small denominators.

Lastly, we performed univariate and multivariable mixed-effects Poisson regression to identify 239 individual (e.g., sex, race/ethnicity, age) and zip-code level (e.g., SVI, racial makeup, health 240 241 insurance coverage) factors independently associated with receiving the primary vaccine series and boosters; in multivariable models, we excluded zip code-level variables that would be expected to 242 relate directly to SVI (e.g., poverty, median income). We applied an established method for using 243 Poisson regression with robust variances to estimate risk ratios from binary outcomes [19,20]. We 244 leveraged vaccination and 2020 census data to estimate the number of unvaccinated individuals 245 across strata of age, sex, and race/ethnicity in each zip code. We visually assessed for linearity in the 246 247 relationship between continuous variables and outcomes and presented variables with nonlinear

relationships as categorical variables (i.e., age, zip code SVI). The effect of race/ethnicity and racism 248 on health outcomes is mediated by (as opposed to confounded by) ecological structural factors such 249 socioeconomic status: thus, unadjusted analyses assess the overall association with race/ethnicity 250and racism while adjusted analyses can be thought to assess the contribution of systemic racism that 251 still remains even when adjusting away the mediating effects of measured ecological factors [21-23]. 252 To account for missingness in race/ethnicity and patient zip code variables, we performed 253 multiple imputation using multivariate normal imputation methods (n=50 imputations) [24-26]. For zip 254 codes, we first transformed them to the latitude and longitude of their centroid, ran the multiple 255 imputation model, and then transformed multiply imputed latitude and longitude values back into zip 256 codes. Missingness was highly dependent on vaccination date and administration site, and thus the 257 missing at random assumption required for unbiased imputation (i.e., that missingness was random 258 259 conditional on all the variables included in the imputation model [administration site, vaccination date, sex, age, race/ethnicity, zip code latitude and longitude, type of vaccine]) was very plausible in our 260 261 setting [24-26].

All analyses were conducted using Stata MP 17.0 and R 3.2.4.

263

264 RESULTS

Between December 15, 2020 to February 15, 2022, 4,741,806 total COVID-19 vaccines were administered to 2,019,715 unique individuals across 7 counties in the St. Louis region and 4 counties in the Kansas City region. Among those receiving at least one dose in St. Louis and Kansas City, 1,762,508 (87.3%) completed the primary series and 871,896 (43.2%) had received a booster. Of those who completed the primary series, approximately 75% of individuals did so prior to June 15 and approximately 25% afterwards (Tables 1a and 1b, Table S1a and S1b).

271

272 Rates of COVID-19 Primary and Booster Vaccinations by Race/Ethnicity and SVI over Time

The rate of primary COVID-19 vaccinations steadily increased until peaking in mid-April. This 273 was followed by rapid decline with smaller upticks at the end of May and then during the Delta wave 274 275 beginning in July; there was no corresponding uptick in vaccination rates during the Omicron wave beginning in mid-December (Figure 1, Table/Figures S2-S5). Up through April, White individuals from 276 zip codes with low SVIs were vaccinated at a rate greater than 2 times that of Black and Hispanic 277 individuals from high SVI zip codes, but the rate ratio declined over time. Asian individuals from all zip 278 279 codes were vaccinated at the highest rates. During the same early period, Black and Hispanic individuals from low-SVI zip codes were vaccinated at rates somewhat similar to or higher than White 280individuals from medium and high SVI zip codes. After June, Black and Hispanic individuals from 281 high, medium, and low SVI zip codes were vaccinated at higher rates than White individuals, although 282 283 this was also during periods with lower absolute numbers of vaccinations (Figure 1, Table/Figures S2-S5). Patterns were largely similar across St. Louis and Kansas City (Figures S4a-S4b). 284

Booster rates increased starting in October 2021 and peaked in early December at the beginning of the Omicron wave, albeit at much lower levels than for the primary vaccine series, and started to decline in January 2022. Patterns of disparities across race/ethnicity were similar for boosters compared to completion of the primary series (Figure 1, Table/Figures S2-S5).

289

290 Locations of COVID-19 Vaccinations Over Time

Early during the vaccination campaign, the vast majority of vaccines were delivered through medium and large volume health facilities (Figure 2). From February through April, a substantial proportion were also delivered through public health departments (including mass vaccination sites). After April, the proportion of vaccines being administered through pharmacies steadily increased accounting for about 70% of vaccines administered after July. Black individuals received

comparatively more vaccines through employer/school sponsored sites, small volume health facilities,
 or other facilities such as dialysis centers, home health, and nursing homes and fewer from
 pharmacies and health departments. Hispanic and Asian individuals received comparatively more
 vaccines through pharmacies and health departments; Hispanic individuals also received relatively
 few vaccines from large volume health facilities. Again, patterns were qualitatively similar for boosters
 (Figure 2).

302

303 COVID-19 Vaccine Disparities across Zip Codes using Lorenz Curves

304 Modified Lorenz curves depict the distribution of COVID-19 vaccinations with respect to the total population, diagnosed COVID-19 cases, deaths, and population-level SVI across zip codes 305 (Figure 3). For the primary vaccine series, zip codes in the guartile with the lowest rates of 306 307 vaccinations accounted for 19.3%, 18.1%, 10.8%, and 8.8% of vaccines but represented 25% of either the total population, cases, deaths, or population-level SVI, respectively. These zip codes, in 308 general, had higher proportions of Black residents, lower median incomes, higher rates of poverty, 309 lower rates of health insurance coverage, a higher proportion of residents employed in the service 310 sector, and higher COVID-19 deaths (Figure 3, Tables S6-S9). In contrast, zip codes with the highest 311 rates of vaccinations accounted for 30.7%, 35.0%, 44.2%, and 56.1% of vaccinations, but 312 represented 25% of either the total population, cases, deaths, or population-SVI, respectively. These 313 zip codes tended to have a lower percentage of Black residents and be more socioeconomically 314 advantaged (Figure 3, Tables S6-S9). These patterns were similar, but demonstrated a greater 315 magnitude of disparities for boosters (Figure 3, Tables S6-S9). 316

When examining changes in Gini coefficients and vaccine inequities between zip codes over time, inequities were extremely high during the initial periods of the primary series rollout, but began to slowly improve after February 2021 relative to population, deaths, and total social vulnerability, but

improvements relative to diagnosed cases plateaued around May 2021. Nevertheless, these
improvements were slow and modest and vaccine inequities between zip codes remained substantial
all metrics through to January 2022 (Figures 4 and S10). With respect to boosters, Gini coefficients
once again were very high in the beginning of rollout, followed by slow improvement with relative to
population, cases, and deaths; Ginis did not improve (and even worsened initially) relative to total
social vulnerability (Figures 4 and S11). There were limited improvements after December 2022

327

328 COVID-19 Vaccine Disparities within Zip Codes

329 Black, Hispanic, and Asian individuals generally had lower rates of primary series completion 330 compared to White individuals residing in the same zip codes in zip codes with lower vaccination coverage (which also tended to have higher SVIs) (Figures 5 and S12). However, in zip codes with 331 high vaccine coverage (which also tended to have low SVIs), Black, Hispanic, and Asian communities 332 often had higher primary series completion compare to White communities in the same zip code. For 333 boosters, Black and Hispanic communities had lower vaccination rates compared to White 334 communities across most zip codes, although Asian communities trended slightly towards have 335 higher booster rates (Figures 5 and S12). 336

337

338 Factors Associated with Receiving the Primary Vaccine Series and Boosters

In multivariable mixed-effects Poisson regression, Black and Hispanic individuals had slightly lower rates of completing the primary vaccine series compared to White individuals (aRRs 0.94 [95% CI 0.93-0.94] and 0.96 [95% CI 0.95-0.97], respectively), while Asian individuals had slightly higher rates (aRRs 1.03 [95% CI 1.02-1.03]). Living in medium and high SVI zip codes was also associated with lower vaccination rates compared to low SVI zip codes (aRRs 0.92 [95% CI 0.91-0.92] and 0.88

[95% CI 0.88-0.89]) (Table 2). Additional factors associated with increased vaccination were being female, being over 55, or between 12 to 19 years old (as compared to 45 to 55 years old); 20 to 34 years olds had decreased vaccination rates. Differences in receipt of a booster vaccine were substantially higher across race, age, sex, and zip code SVI compared to the differences in completion of the primary vaccine series, except that 12- to 19-year-olds were less likely to receive a booster (Table 2).

350

351 DISCUSSION

352 Our analyses characterized disparities in the COVID-19 vaccination campaign in the St. Louis and Kansas City regions across racial/ethnic communities, across levels of social vulnerability, over 353 354 time, and across types of vaccine administrations sites. We describe changes in the rates of receiving 355 the primary COVID-19 vaccination series and boosters across race/ethnicity and social vulnerability 356 and highlight how these changes corresponded with shifts in the types of locations where vaccines individuals were being vaccinated. We also use Lorenz curves and Gini coefficients to quantify 357 disparities in vaccinations with respect to population, COVID-19 related disease burden, and social 358 vulnerability. Overall, these results provide a deeper characterization the systemic inequities in 359 distribution of one of the most critical (and initially scarce) resources for controlling the COVID-19 360 pandemic but one that is immediately actionable: COVID-19 vaccinations. 361

These analyses provide a deeper understanding of the patterns of vaccine inequities over time, and note that disparities were greatest earlier on but have also largely persisted over time with minimal improvement since April 2020. Furthermore, they emerged anew with the booster rollout in Fall 2021. Early during vaccination, rates of completing the primary vaccine series were highest among White and Asian individuals in zip codes with low SVIs. During this early period a vast majority of vaccines were administered through health systems and also mass vaccination sites coordinated

by public health departments. The relationship between race/ethnicity and zip code SVI is salient 368 during this period: Black and Hispanic individuals living in high SVI zip codes had strikingly lower 369 rates of vaccination compared to other groups, whereas Black and Hispanic individuals in low SVI zip 370 codes had similar to somewhat higher rates compared to White individuals in medium and high SVI 371 zip codes. Over time, and particularly after all adults became eligible for vaccination, rates of 372 vaccinations among Black and Hispanic individuals across all SVI zip codes started to exceed those 373 among White individuals. During these periods, sites of vaccine administration also diversified and 374 shifted more towards pharmacies and other small community-based sites (and were much less likely 375 to occur at very large facilities). When quantifying these disparities using Lorenz curves, we note that 376 disparities in vaccinations were highest relative to population-level social vulnerability and deaths, but 377 still evident-albeit reduced-even when considering vaccinations relative to the overall population 378 379 and diagnosed COVID-19 cases. Lastly, when examining disparities within zip codes, we see consistently higher rates of vaccination among White individuals compared to Black individuals, with 380 381 the starkest difference in high SVI zip codes. Unfortunately, despite the slow progress from the early periods in improving equity in completion of the primary vaccine series, the same patterns of 382 disparities were repeated again during the booster rollout, and were often of greater magnitude. 383

It is critical to understand these trends in the context of the underlying structural driving forces 384 385 and decisions leading to these vaccination patterns, both of which are relevant nationally and not specific to Missouri. First, the high levels of disparities seen in the earlier stages of the primary 386 vaccine series and booster rollout likely reflects the fact that health care workers and older individuals 387 were eligible for vaccination first, factors that are also associated with higher socioeconomic status 388 and lower SVI [9,10]. Second, the early phases for the primary vaccine series occurred primarily at 389 sites associated with large health systems. However, these are also the sites from which Black and 390 Hispanic individuals—and particularly those from high SVI zip codes—were comparatively less likely 391 to ultimately receive vaccinations, highlighting a critical issue related to vaccine access among 392

racially and ethnically marginalized and socially vulnerable communities [27-32]. Although large 393 health systems may have been more readily able to overcome logistic issues and provide the robust 394 395 cold chain needed for mRNA vaccines, they have limited mandates and expertise for implementing large-scale public health initiatives. Even prior to the pandemic, the significant disparities in who 396 accesses care at these health systems and who is outside of them were well-known [30,33]. Physical 397 access, challenges with scheduling (particularly online), disparities in insurance, lack of community 398 399 partnerships, and mistrust of large institutions that have largely neglected underserved communities often serve as salient barriers to care-seeking in large health systems for individuals from high SVI 400 communities [27,30,34,35]. Vaccination campaigns are a public health strategy that requires broad 401 reach into communities that large health systems did not have and were not designed for; thus, the 402 403 strategies relying on these systems did not reach the most vulnerable populations essentially by design even though the vaccines themselves were freely available. These patterns seen in both the 404primary vaccine series and booster rollout were also mirrored in prior research from our group 405 examining disparities in COVID-19 testing, and their origins can be traced back to many of the same 406 root causes [4]. Ultimately, the repeated reliance on systems with a history of providing lower access 407 to certain segments of the population is representative of how structural inequities also became 408 embedded in vaccine rollout from its onset and serves as a precautionary tale, albeit one that has 409 410 been told too many times before.

Overall vaccinations rates and patterns over time in Black and Hispanic populations and high SVI zip codes further underscores the deeply embedded systemic nature of racialized disparities and the highly intersectional nature of systemic racism and social vulnerability [1,27-30,33-35]. Even though several vaccination strategies sought to prioritize Black and Hispanic individuals living in high SVI zip codes given their high burden of disease earlier on [11,12,36-38], they still had dramatically lower vaccination rates compared to White and Asian individuals in the same high SVI zip codes and those from zip codes with low SVIs. As the initial vaccine rollout progressed, though, rates in Black

and Hispanic populations did eventually exceed those in White (though not Asian) populations. This 418 coincided with wider vaccine availability and the shift toward vaccine administration at smaller centers 419 such as pharmacies. Again, these changes in vaccination rates over time may be indicative of the 420 increased access to vaccinations in Black. Hispanic, and other socially vulnerable communities 421 through community-based settings as opposed to large health systems [30.34,37,39]. These patterns 422 must also be contextualized within the growing literature on vaccine confidence and hesitancy. 423 Vaccine hesitancy is not monolithic and ranges from beliefs in conspiracy theories and skepticism 424 about COVID-19 to more nuanced concerns regarding safety, side effects, inability to take time off 425 work, observing others safely vaccinated (i.e., social proof), and lack of trusted messaging [29,33-426 35,40-42]; its patterns and trends across communities also varies [43,44]. Qualitative studies have 427 shown that lack of vaccine confidence in Black communities in particular stems largely from histories 428 of systematic mistreatment and racism-which includes failed contemporary responses to COVID-429 -leading to mistrust of larger institutions and concerns over bearing the burden of unfavorable 430 safety and side effect profiles (particularly given the rapid timeline of development and shifting 431 messaging over the need for additional doses) [29,35]. However, rates of primary series completion in 432 the Black population also likely increased as confidence in vaccinations improved over time, more of 433 the population was safely vaccinated (i.e., social proof), purposeful and targeted messaging was 434 435 delivered from trusted sources, and there were more opportunities to discuss specific questions and concerns with trusted health care providers [43,44]. Although a common pattern with the diffusion of 436 many innovations, it is critical to contextualize the structural disparities leading to this late adoption. 437

Although multiple strategies were put forth early in order prioritize equitable vaccination, our analysis shows that we were far from achieving such goals when examined from several metrics. Early vaccine allocation strategies designed to maximize benefits when supply was limited included considerations for prioritizing groups with higher risk for COVID-19 exposure or who had experienced higher burden of COVID-19 disease using metrics such as geography, social vulnerability index, or

race/ethnicity (in addition to using age, comorbidities, high risk occupations) [11-13.36-38]. Still, these 443 strategies mostly focused on determining vaccine eligibility, but eligibility or availability of vaccines 444 445 doesn't equate to adequate access. Indeed, achieving equity would have also required early concomitant prioritization and efforts to target structural barriers to vaccine uptake and reasons for 446 later adoption [45]. Several programs demonstrated success using early, low barrier, and widely 447 available access to vaccines at community-based sites (as opposed to mass vaccination sites and 448 large health systems, often requiring online registration) in areas with high social vulnerability coupled 449 with abundant opportunities to connect with and discuss concerns with trusted sources of information 450 [30,34,41,46-50]. A program in San Francisco leveraged a community-based vaccination site near a 451 transportation hub to target both access and trust-related barriers, and leveraged both high-touch 452 (e.g., going door-to-door to provide information and register individuals) and low-touch methods (e.g., 453 flyers and advertisements [50]. Approaches like these are even more important during the later 454 stages of vaccination roll-out, when large or mass vaccination sites—which allowed for high volume 455 456 for those already eager to be vaccinated—are likely at the limits of their reach.

457 There are several limitations to our analysis. First, reporting of all vaccinations was mandated 458 by the state, but race/ethnicity and zip code were not reported consistently, particularly at smaller 459 sites. Still, as this missingness was highly dependent on the vaccination date and site date, multiple 460 imputation would still yield unbiased results even with higher levels of missingness [24-26]. Second, there may also have been misclassification of zip codes of individuals if permanent addresses did not 461 match where people were actually living at the time of vaccination or in our categorization of vaccine 462 location types. However, any misclassification was likely small and there is no reason to believe that 463 there was systemic error that would substantially bias our results. Third, we used zip code population 464 estimates from the 2020 census data, but true population sizes-and thus the appropriate 465 denominators for some analyses-may have changed since then, particularly due to the well-466 documented migrations that occurred during the early phases of the pandemic. Fourth, we lacked 467

complementary data that could help contextualize our findings (e.g., association between 468 race/ethnicity and time or vaccine location type) and help characterize the relationship with potential 469 drivers of these disparities, such as occupation, health insurance status, linkage to primary care, and 470 vaccination awareness, knowledge, beliefs, and intentions. Fourth, in this analysis we were unable to 471 provide more granular details on other racial/ethnic minorities such as indigenous or multi-racial 472 individuals, either due to small populations in the regions or inability to link these population across 473 data sources. Still, although we do include Black, White, Hispanic, and Asian communities, it remains 474 critical to also assess disparities across other minoritized communities, acknowledging that the 475 multidimensional nature of health disparities and unique drivers across these different communities 476 warrants dedicated attention and public health action. 477

In conclusion, we provide nuanced characterizations of the disparities in COVID-19 vaccination 478 479 across racial/ethnic communities, across levels of social vulnerability, over time, and across types of vaccine administration sites after one year of vaccination. Equitable COVID-19 vaccination is one of 480 the most critical targets for successfully ending the pandemic, but, despite substantial discussion on 481 482 how to effectively do so, it is clear that our strategies-both nationally and in Missouri-have yet to 483 overcome the deeply entrenched systemic inequities in health care and society. Future planning for 484 proactive and considered public health strategies in the face of pandemic emergencies—as opposed 485 to reactive approaches—are needed to ensure that our responses are equitable from the outset and do not disproportionately affect minority communities both in the United States and globally. 486

487

488

490 **REFERENCES**

Bibbins-Domingo K. This Time Must Be Different: Disparities During the COVID-19 Pandemic. Ann 491 1. 492 Intern Med. 2020:173(3):233-4. Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and Ethnic Disparities in 493 COVID-19-Related Infections, Hospitalizations, and Deaths. Annals of Internal Medicine. 2020;174(3):362-73. 494 495 Miller S, Wherry LR, Mazumder B. Estimated Mortality Increases During The COVID-19 Pandemic By 3. 496 Socioeconomic Status, Race, And Ethnicity. Health Affairs. 2021;40(8):1252-60. 497 Mody A, Pfeifauf K, Bradley C, Fox B, Hlatshwayo MG, Ross W, et al. Understanding Drivers of 498 Coronavirus Disease 2019 (COVID-19) Racial Disparities: A Population-Level Analysis of COVID-19 Testing 499 Among Black and White Populations. Clin Infect Dis. 2021;73(9):e2921-e31. 500 Bajos N, Jusot F, Pailhé A, Spire A, Martin C, Meyer L, et al. When lockdown policies amplify social 501 inequalities in COVID-19 infections: evidence from a cross-sectional population-based survey in France. BMC 502 Public Health. 2021;21(1):705. 503 Zhou M, Kan M-Y. The varying impacts of COVID-19 and its related measures in the UK: A year in 6 504 review. PLoS ONE. 2021;16(9):e0257286. Galea S, Abdalla SM. COVID-19 Pandemic, Unemployment, and Civil Unrest: Underlying Deep Racial 505 7. 506 and Socioeconomic Divides. JAMA. 2020;324(3):227-8. 507 Benfer EA, Vlahov D, Long MY, Walker-Wells E, Pottenger JL, Jr., Gonsalves G, et al. Eviction, Health 8. 508 Inequity, and the Spread of COVID-19: Housing Policy as a Primary Pandemic Mitigation Strategy. J Urban 509 Health. 2021;98(1):1-12. 510 9 National Academies of Sciences E, and Medicine. Framework for Equitable Allocation of COVID-19 511 Vaccine. Washington, DC: The National Academies Press; 2020. 512 Bell BP, Romero JR, Lee GM. Scientific and Ethical Principles Underlying Recommendations From the 10. 513 Advisory Committee on Immunization Practices for COVID-19 Vaccination Implementation. JAMA. 514 2020;324(20):2025-6. 515 Schmidt H, Weintraub R, Williams MA, Miller K, Buttenheim A, Sadecki E, et al. Equitable allocation of 11. 516 COVID-19 vaccines in the United States. Nature Medicine. 2021;27(7):1298-307. 517 12. Wrigley-Field E, Kiang MV, Riley AR, Barbieri M, Chen Y-H, Duchowny KA, et al. Geographically 518 targeted COVID-19 vaccination is more equitable and averts more deaths than age-based thresholds alone. 519 Science Advances. 2021;7(40):eabj2099. 520 Srivastava T, Schmidt H, Sadecki E, Kornides ML. Disadvantage Indices Deployed to Promote 13. Equitable Allocation of COVID-19 Vaccines in the US: A Scoping Review of Differences and Similarities in 521 522 Design, JAMA Health Forum, 2022;3(1):e214501-e. Lorenz MO. Methods of Measuring the Concentration of Wealth. Publications of the American 523 14. 524 Statistical Association. 1905;9(70):209-19. 525 Centers for Disease Control and Prevention/ Agency for Toxic Substances and Disease Registry/ 15. 526 Geospatial Research A, and Services Program. CDC/ATSDR Social Vulnerability Index 2018 Database 527 [Available from: https://www.atsdr.cdc.gov/placeandhealth/svi/data documentation download.html. 528 Christopoulos KA, Hartogensis W, Glidden DV, Pilcher CD, Gandhi M, Geng EH. The Lorenz curve: a 16. 529 novel method for understanding viral load distribution at the population level. AIDS. 2017;31(2):309-10. 530 Mauguen A, Begg CB. Using the Lorenz Curve to Characterize Risk Predictiveness and Etiologic 17. 531 Heterogeneity. Epidemiology. 2016;27(4):531-7. Rita Neves Costa SbPr-D. Statistics Paper Series: Not all inequality measures were created equal. 532 18. 533 ECB Statistics Paper Series. December 2019;31. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J 534 19. 535 Epidemiol. 2004;159(7):702-6. Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with 536 20. 537 correlated binary data. Stat Methods Med Res. 2013;22(6):661-70. 538 21. Jones CP. Invited commentary: "race," racism, and the practice of epidemiology. Am J Epidemiol. 539 2001;154(4):299-304; discussion 5-6. Chowkwanyun M, Reed AL, Jr. Racial Health Disparities and Covid-19 - Caution and Context. N Engl J 540 22. 541 Med. 2020;383(3):201-3.

542 23. Boyd RW, Lindo EG, Weeks LD, McLemore MR. On Racism: A New Standard For Publishing On 543 Racial Health Inequities [Internet]: Health Affairs Blog. 2020. Lee KJ, Carlin JB. Multiple imputation for missing data: fully conditional specification versus multivariate 544 24. 545 normal imputation. Am J Epidemiol. 2010:171(5):624-32. 546 Madley-Dowd P, Hughes R, Tilling K, Heron J. The proportion of missing data should not be used to 25. 547 guide decisions on multiple imputation. J Clin Epidemiol. 2019;110:63-73. 548 Bernaards CA, Belin TR, Schafer JL. Robustness of a multivariate normal approximation for imputation 26. 549 of incomplete binary data. Stat Med. 2007;26(6):1368-82. 550 Jean-Jacques M, Bauchner H. Vaccine Distribution—Equity Left Behind? JAMA. 2021;325(9):829-30. 27. 551 Thakore N, Khazanchi R, Orav EJ, Ganguli I. Association of Social Vulnerability, COVID-19 vaccine site 28. 552 density, and vaccination rates in the United States. Healthcare. 2021;9(4):100583. 553 29 Balasuriya L, Santilli A, Morone J, Ainooson J, Roy B, Njoku A, et al. COVID-19 Vaccine Acceptance 554 and Access Among Black and Latinx Communities. JAMA Network Open. 2021;4(10):e2128575-e. 555 Njoku A, Joseph M, Felix R. Changing the Narrative: Structural Barriers and Racial and Ethnic 30. 556 Inequities in COVID-19 Vaccination. International journal of environmental research and public health. 557 2021;18(18):9904. 558 31. Blackstock U, Blackstock O. White Americans are being vaccinated at higher rates than Black 559 Americans. Such inequity cannot stand.: Washington Post; February 1, 2021 [Available from: 560 https://www.washingtonpost.com/opinions/2021/02/01/racial-inequality-covid-vaccine/. 32. Boyd R. Black People Need Better Vaccine Access, Not Better Vaccine Attitudes: New York Times; 561 March 5, 2021 [Available from: https://www.nytimes.com/2021/03/05/opinion/us-covid-black-people.html. 562 563 33. Levesque JF, Harris MF, Russell G. Patient-centred access to health care: conceptualising access at 564 the interface of health systems and populations. Int J Equity Health. 2013;12:18. 565 Marcelin JR, Swartz TH, Bernice F, Berthaud V, Christian R, da Costa C, et al. Addressing and 34. 566 Inspiring Vaccine Confidence in Black, Indigenous, and People of Color During the Coronavirus Disease 2019 567 Pandemic. Open forum infectious diseases. 2021;8(9):ofab417-ofab. Momplaisir F, Haynes N, Nkwihoreze H, Nelson M, Werner RM, Jemmott J. Understanding Drivers of 568 35. 569 COVID-19 Vaccine Hesitancy Among Blacks. Clin Infect Dis. 2021. 570 36. Ndugga N, Artiga S, Pham O. How are States Addressing Racial Equity in COVID-19 Vaccine Efforts? : 571 Kaiser Family Foundation; March 10, 2021 [Available from: https://www.kff.org/racial-equity-and-health-572 policy/issue-brief/how-are-states-addressing-racial-equity-in-covid-19-vaccine-efforts/. 573 Bibbins-Domingo K, Petersen M, Havlir D. Taking Vaccine to Where the Virus Is-Equity and 37. 574 Effectiveness in Coronavirus Vaccinations. JAMA Health Forum. 2021;2(2):e210213-e. 575 Schmidt H. Gostin LO. Williams MA. Is It Lawful and Ethical to Prioritize Racial Minorities for COVID-19 38. 576 Vaccines? JAMA. 2020;324(20):2023-4. 577 39. Corallo B, Artiga S, Tolbert J. Are Health Centers Facilitating Equitable Access to COVID-19 578 Vaccinations? : Kaiser Family Foundation; June 02, 2021 [Available from: https://www.kff.org/coronavirus-579 covid-19/issue-brief/are-health-centers-facilitating-equitable-access-to-covid-19-vaccinations-a-june-2021-580 update/. 581 Tram KH, Saeed S, Bradley C, Fox B, Eshun-Wilson I, Mody A, et al. Deliberation, Dissent, and 40. 582 Distrust: Understanding distinct drivers of COVID-19 vaccine hesitancy in the United States. Clin Infect Dis. 583 2021. 584 Corbie-Smith G. Vaccine Hesitancy Is a Scapegoat for Structural Racism. JAMA Health Forum. 41. 585 2021:2(3):e210434-e. Eshun-Wilson I, Mody A, Tram KH, Bradley C, Sheve A, Fox B, et al. Preferences for COVID-19 586 42. 587 vaccine distribution strategies in the US: A discrete choice survey. PLoS ONE. 2021;16(8):e0256394-e. 588 Padamsee TJ, Bond RM, Dixon GN, Hovick SR, Na K, Nisbet EC, et al. Changes in COVID-19 Vaccine 43. 589 Hesitancy Among Black and White Individuals in the US. JAMA Netw Open. 2022;5(1):e2144470. 590 Daly M, Jones A, Robinson E. Public Trust and Willingness to Vaccinate Against COVID-19 in the US 44. 591 From October 14, 2020, to March 29, 2021. JAMA. 2021;325(23):2397-9. 592 45. Hardeman A, Wong T, Denson JL, Postelnicu R, Rojas JC. Evaluation of Health Equity in COVID-19 593 Vaccine Distribution Plans in the United States. JAMA Network Open. 2021;4(7):e2115653-e.

- Abdul-Mutakabbir JC, Casey S, Jews V, King A, Simmons K, Hogue MD, et al. A three-tiered approach
 to address barriers to COVID-19 vaccine delivery in the Black community. The Lancet Global health.
 2021;9(6):e749-e50.
- 47. Galaviz KI, Breland JY, Sanders M, Breathett K, Cerezo A, Gil O, et al. Implementation Science to Address Health Disparities During the Coronavirus Pandemic. Health Equity. 2020;4(1):463-7.
- 599 48. Faherty LJ, Ringel JS, Williams MV, Kranz AM, Perez L, Schulson L, et al. Early Insights from the 600 Equity-First Vaccination Initiative. Santa Monica, CA: RAND Corporation; 2021.
- 49. Beste Lauren A, Chen A, Geyer J, Wilson M, Schuttner L, Wheat C, et al. Best Practices for an Equitable Covid-19 Vaccination Program. NEJM Catalyst.2(10).
- 50. Marguez C, Kerkhoff AD, Naso J, Contreras MG, Castellanos Diaz E, Rojas S, et al. A multi-
- 604 component, community-based strategy to facilitate COVID-19 vaccine uptake among Latinx populations: From 605 theory to practice. PLoS ONE. 2021;16(9):e0257111-e.

Table 1a. Characte	ristics of individ	duals completing	ng primary seri	es				
	<u>Overall</u> (n =1,762,508)	<u>Black</u> (n=226,459)	<u>White</u> (n=1,088,834)	<u>Hispanic</u> (n =60,066)	Hispanic Asian SVI (High) SVI (Medium) n =60,066) (n=47,819) (n=202,627) (n=527,664)		<u>SVI (Low)</u> (n=1,032,217)	
Sex*, n (%)								
Male	797,650	92,535	503,284	29,859	22,403	86,560	237,040	474,050
	(45.3%)	(40.9%)	(46.2%)	(49.7%)	(46.9%)	(42.8%)	(45.0%)	(46.0%)
Female	962,994	133,866	585,354	30,174	25,392	115,832	289,827	557,335
	(54.7%)	(59.1%)	(53.8%)	(50.3%)	(53.1%)	(57.2%)	(55.0%)	(54.0%)
Age Category*, n (%)								
12-19 years	160,187	23,038	93,945	8,363	5,227	18,718	42,966	98,503
	(9.1%)	(10.2%)	(8.6%)	(13.9%)	(10.9%)	(9.2%)	(8.1%)	(9.5%)
20-34 years	331,810	41,749	199,457	16,725	14,888	39,559	105,291	186,960
	(18.8%)	(18.4%)	(18.3%)	(27.8%)	(31.1%)	(19.5%)	(20.0%)	(18.1%)
35-44 years	257,328	32,389	156,796	11,322	9,127	29,369	74,321	153,638
	(14.6%)	(14.3%)	(14.4%)	(18.8%)	(19.1%)	(14.5%)	(14.1%)	(14.9%)
45-54 years	250,925	36,557	151,304	9,400	7,798	29,641	73,123	148,161
	(14.2%)	(16.1%)	(13.9%)	(15.6%)	(16.3%)	(14.6%)	(13.9%)	(14.4%)
55-64 years	303,951	43,314	192,070	7,428	5,184	37,069	93,515	173,367
	(17.2%)	(19.1%)	(17.6%)	(12.4%)	(10.8%)	(18.3%)	(17.7%)	(16.8%)
65-74 years	263,282	31,411	170,422	4,342	3,501	29,318	80,562	153,402
	(14.9%)	(13.9%)	(15.7%)	(7.2%)	(7.3%)	(14.5%)	(15.3%)	(14.9%)
75+ years	195,025	18,001	124,840	2,486	2,094	18,953	57,886	118,186
	(11.1%)	(7.9%)	(11.5%)	(4.1%)	(4.4%)	(9.4%)	(11.0%)	(11.4%)
Race*, n (%)								
Black	226,459 (13.3%)	-	-	-	-	99,427 (50.7%)	84,172 (16.6%)	42,860 (4.3%)
White	1,088,834 (64.1%)	-	-	-	-	48,610 (24.8%)	310,289 (61.4%)	729,935 (73.2%)

Hispanic	60,066 (3.5%)	-	-	-	-	13,040 (6.7%)	19,738 (3.9%)	27,288 (2.7%)
Asian	47,819 (2.8%)	-	-	-	-	3,312 (1.7%)	13,333 (2.6%)	31,174 (3.1%)
Other	274,977 (16.2%)	-	-	-	-	31,669 (16.2%)	78,007 (15.4%)	165,301 (16.6%)
Median Zip Code	0.29	0.57	0.25	0.37	0.24	0.79	0.47	0.18
SVI, (IQR)	(0.31)	(0.39)	(0.26)	(0.43)	(0.28)	(0.12)	(0.12)	(0.12)
Vaccine Location Type, n (%)								
Small Volume	53,786	9,473	31,823	1,631	982	7,617	16,854	29,315
Health Facility	(3.1%)	(4.2%)	(2.9%)	(2.7%)	(2.1%)	(3.8%)	(3.2%)	(2.8%)
Medium Volume	246,879	28,435	156,814	8,630	5,743	25,426	72,552	148,901
Health Facility	(14.0%)	(12.6%)	(14.4%)	(14.4%)	(12.0%)	(12.5%)	(13.7%)	(14.4%)
Large Volume	423,935	51,541	276,743	7,798	10,018	39,685	115,636	268,614
Health Facility	(24.1%)	(22.8%)	(25.4%)	(13.0%)	(20.9%)	(19.6%)	(21.9%)	(26.0%)
Pharmacy	655,107	80,424	389,969	28,618	18,312	81,772	205,822	367,513
	(37.2%)	(35.5%)	(35.8%)	(47.6%)	(38.3%)	(40.4%)	(39.0%)	(35.6%)
Health	304,869	40,779	192,470	11,164	10,594	36,292	93,509	175,068
Department	(17.3%)	(18.0%)	(17.7%)	(18.6%)	(22.2%)	(17.9%)	(17.7%)	(17.0%)
Employer/School	39,272	7,957	21,030	981	1,613	5,700	12,397	21,175
	(2.2%)	(3.5%)	(1.9%)	(1.6%)	(3.4%)	(2.8%)	(2.3%)	(2.1%)
Other	38,660	7,850	19,985	1,244	557	6,135	10,894	21,631
	(2.2%)	(3.5%)	(1.8%)	(2.1%)	(1.2%)	(3.0%)	(2.1%)	(2.1%)
Primary Series								
J&J	115,350	18,352	71,569	4,656	2,269	16,174	37,860	61,316
	(6.5%)	(8.1%)	(6.6%)	(7.8%)	(4.7%)	(8.0%)	(7.2%)	(5.9%)

Moderna	485,101	59,385	286,032	16,353	10,976	59,390	156,016	269,695
	(27.5%)	(26.2%)	(26.3%)	(27.2%)	(23.0%)	(29.3%)	(29.6%)	(26.1%)
Pfizer	116,2057	148,722	731,233	39,057	34,574	127,063	333,788	701,206
	(65.9%)	(65.7%)	(67.2%)	(65.0%)	(72.3%)	(62.7%)	(63.3%)	(67.9%)
Booster Received,	928,776	95,760	601,731	22,275	25,512	83,363	262,900	582,513
(n%)	(52.7%)	(42.3%)	(55.3%)	(37.1%)	(53.4%)	(41.1%)	(49.8%)	(56.4%)
Time Period, n (%)								
Dec 15, 20 –	1430,852	153,684	916,414	42,993	41,462	138,701	415,754	876,397
Jun 15, 21	(81.2%)	(67.9%)	(84.2%)	(71.6%)	(86.7%)	(68.5%)	(78.8%)	(84.9%)
Jun 16, 21 –	311,635	67,322	162,767	15,696	5,814	59,428	105,018	147,189
Dec 15, 21	(17.7%)	(29.7%)	(14.9%)	(26.1%)	(12.2%)	(29.3%)	(19.9%)	(14.3%)
Dec 16, 21 –	20,021	5,453	9,653	1,377	543	4,498	6,892	8,631
Feb 15, 22	(1.1%)	(2.4%)	(0.9%)	(2.3%)	(1.1%)	(2.2%)	(1.3%)	(0.8%)

607 Footnote: *Overall Missing values: Sex: 1,866; Race: 64,353; Zip code: 128. Abbreviations: SVI – Social Vulnerability Index; J&J – Johnson and 608 Johnson

Table 1b. Character	istics of individua	als	s receiving a	booster vacc	ination				
	<u>Overall</u> (n =871,896)		<u>Black</u> (n=84,525)	<u>White</u> (n=569,128)	<u>Hispanic</u> (n=20,072)	<u>Asian</u> (n=23,399)	<u>SVI (High)</u> (n=74,193)	<u>SVI (Medium)</u> (n=245,056)	<u>SVI (Low)</u> (n=552,647)
Sex*, n (%)									
Male	375,579 (43.1%)		32,938 (39.0%)	250,101 (43.9%)	9,309 (46.4%)	10,752 (46.0%)	29,862 (40.3%)	104,250 (42.6%)	241,467 (43.7%)
Female	4961,78 (56.9%)		51,583 (61.0%)	319,001 (56.1%)	10,762 (53.6%)	12,641 (54.0%)	44,319 (59.7%)	140,742 (57.4%)	311,117 (56.3%)
Age Category*, n (%)									
12-19 years	41,111 (4.7%)		3,288 (3.9%)	26,431 (4.6%)	1,586 (7.9%)	1,826 (7.8%)	2,370 (3.2%)	8,896 (3.6%)	29,845 (5.4%)
20-34 years	110,347 (12.7%)		7,699 (9.1%)	71,940 (12.6%)	3,982 (19.8%)	6,178 (26.4%)	7,913 (10.7%)	32,652 (13.3%)	69,782 (12.6%)
35-44 years	111,641 (12.8%)		8,625 (10.2%)	73,835 (13.0%)	3,441 (17.1%)	4,614 (19.7%)	7,847 (10.6%)	28,746 (11.7%)	75,048 (13.6%)
45-54 years	118,526 (13.6%)		13,498 (16.0%)	75,512 (13.3%)	3,537 (17.6%)	4,298 (18.4%)	10,052 (13.5%)	31,469 (12.8%)	77,005 (13.9%)
55-64 years	169,775 (19.5%)		20,779 (24.6%)	110,725 (19.5%)	3,496 (17.4%)	2,926 (12.5%)	16,791 (22.6%)	49,642 (20.3%)	103,342 (18.7%)
65-74 years	181,916 (20.9%)		19,322 (22.9%)	120,021 (21.1%)	2,533 (12.6%)	2,198 (9.4%)	17,515 (23.6%)	53,771 (21.9%)	110,630 (20.0%)
75+ years	138,580 (15.9%)		11,314 (13.4%)	90,664 (15.9%)	1,497 (7.5%)	1,359 (5.8%)	11,705 (15.8%)	39,880 (16.3%)	86,995 (15.7%)
Race*, n (%)									
Black	84,525 (9.9%)		-	-	-	-	33,701 (46.2%)	32,522 (13.6%)	18,302 (3.4%)
White	569,128 (66.5%)		-	-	-	-	21,723 (29.8%)	152,836 (63.8%)	394,569 (72.6%)

Hispanic	20,072 (2.3%)	-	-	-	-	2,735 (3.8%)	6,183 (2.6%)	11,154 (2.1%)
Asian	23,399 (2.7%)	-	-	-	-	1,251 (1.7%)	6,166 (2.6%)	15,982 (2.9%)
Other	159,057 (18.6%)	-	-	-	-	13,494 (18.5%)	41,817 (17.5%)	103,746 (19.1%)
Madian Zin Cada	0.05	0.57	0.00	0.24	0.00	0.70	0.47	0.17
SVI, (IQR)	(0.31)	(0.43)	(0.22)	(0.31)	(0.27)	(0.14)	(0.12)	(0.17)
Booster Location Type, n (%)								
Small Volume Health Facility	41,162 (4.7%)	7,056 (8.3%)	25,891 (4.5%)	801 (4.0%)	949 (4.1%)	5,177 (7.0%)	11,591 (4.7%)	24,394 (4.4%)
Medium Volume Health Facility	86,685 (9.9%)	12,226 (14.5%)	51,772 (9.1%)	1,812 (9.0%)	2,289 (9.8%)	9,602 (12.9%)	21,985 (9.0%)	55,098 (10.0%)
Large Volume Health Facility	71,377 (8.2%)	9,288 (11.0%)	47,160 (8.3%)	956 (4.8%)	1,856 (7.9%)	6,611 (8.9%)	19,927 (8.1%)	44,839 (8.1%)
Pharmacy	610,162 (70.0%)	46,377 (54.9%)	409,512 (72.0%)	14,516 (72.3%)	17,044 (72.8%)	44,051 (59.4%)	169,978 (69.4%)	396,133 (71.7%)
Health Department	37,420 (4.3%)	6,512 (7.7%)	21,872 (3.8%)	1,367 (6.8%)	606 (2.6%)	5,987 (8.1%)	14,179 (5.8%)	17,254 (3.1%)
Employer/School	6,467 (0.7%)	589 (0.7%)	3,767 (0.7%)	177 (0.9%)	473 (2.0%)	385 (0.5%)	2,106 (0.9%)	3,976 (0.7%)
Other	18,623 (2.1%)	2,477 (2.9%)	9,154 (1.6%)	443 (2.2%)	182 (0.8%)	2,380 (3.2%)	5,290 (2.2%)	10,953 (2.0%)
Booster Vaccine Type, n (%)								
J&J	8,795 (1.0%)	1,747 (2.1%)	5,183 (0.9%)	306 (1.5%)	118 (0.5%)	1,363 (1.8%)	2,972 (1.2%)	4,460 (0.8%)

Moderna	293,710	26,927	189,204	7,173	7,123	26,353	86,411	180,946
	(33.7%)	(31.9%)	(33.2%)	(35.7%)	(30.4%)	(35.5%)	(35.3%)	(32.7%)
Pfizer	569,391	55,851	374,741	12,593	16,158	46,477	155,673	367,241
	(65.3%)	(66.1%)	(65.8%)	(62.7%)	(69.1%)	(62.6%)	(63.5%)	(66.5%)
Time Period, n (%)								
Dec 15, 20 –	9,617	1,068	6,031	253	203	943	2,724	5,950
Jun 15, 21	(1.1%)	(1.3%)	(1.1%)	(1.3%)	(0.9%)	(1.3%)	(1.1%)	(1.1%)
Jun 16, 21 –	592,550	50,080	390,151	11,309	13,504	45,748	164,184	382,618
Dec 15, 21	(68.0%)	(59.2%)	(68.6%)	(56.3%)	(57.7%)	(61.7%)	(67.0%)	(69.2%)
Dec 16, 21 –	269,729	33,377	172,946	8,510	9,692	27,502	78,148	164,079
Feb 15, 22	(30.9%)	(39.5%)	(30.4%)	(42.4%)	(41.4%)	(37.1%)	(31.9%)	(29.7%)

Footnote: *Overall Missing values: Sex: 139; Race/Ethnicity: 15,741; Zip code: 40. Abbreviations: SVI – Social Vulnerability Index; J&J – Johnson
 and Johnson

Table 2. Poisson Model of Individual- and Zip Code-Level Factors Associated with Receipt of Primary COVID-19 Vaccination Series and Booster

		Primary	/ Series		Booster			
	Unadjusted Risk Ratio (95% CI)	p-value	Adjusted Risk Ratio (95% CI)	p-value	Unadjusted Risk Ratio (95% CI)	p-value	Adjusted Risk Ratio (95% CI)	p-value
Race/Ethnicity								
Black	0.86 (0.86-0.86)		0.94 (0.93-0.94)		0.65 (0.66-0.66)		0.83 (0.82-0.83)	
White	1 (REF)		1 (REF)		1 (REF)		1 (REF)	
Hispanic	0.89 (0.88-0.89)	<0.001	0.96 (0.95-0.97)	<0.001	0.60 (0.59-0.60)	<0.001	0.76 (0.75-0.77)	<0.001
Asian	1.00 (0.99-1.00)		1.03 (1.02-1.03)		0.96 (0.95-0.97)		1.08 (1.07-1.09)	
Other	1.72 (1.71-1.72)		1.65 (1.65-1.66)		1.88 (1.88-1.89)		1.76 (1.76-1.77)	
Age Catagon								
Age Category	1 20		1.07		0.77		0.76	
12-19 years	(1.28-1.29)	-	(1.26-1.27)	-	(0.77-0.78)		(0.75-0.76)	-
20-34 years	0.83 (0.83-0.83)		0.84 (0.84-0.84)	_	0.59 (0.59-0.60)		0.61 (0.60-0.61)	
35-44 years	1.01 (1.01-1.02)		1.01 (1.01-1.01)		0.92 (0.92-0.93)		0.92 (0.92-0.93)	
45-54 years	1 (REF)	<0.001	1 (REF)	<0.001	1 (REF)	<0.001	1 (REF)	<0.001
55-64 years	1.11 (1.11-1.12)		1.11 (1.10-1.11)	-	1.31 (1.30-1.32)		1.29 (1.28-1.30)	_
65-74 years	1.34 (1.33-1.34)		1.30 (1.30-1.30)	-	1.93 (1.92-1.94)		1.83 (1.82-1.84)	
>75 years	1.31 (1.31-1.31)	-	1.24 (1.24-1.25)	-	1.93 (1.92-1.94)		1.77 (1.76-1.78)	
Sex								
Male	1 (REF)	~0.001	1 (REF)	~0.001	1 (REF)	~0.001	1 (REF)	~0.001
Female	1.09 (1.08 -1.09)	∼0.001	1.07 (1.07-1.07)	∼0.001	1.19 (1.18 -1.19)	<0.001	1.13 (1.13-1.14)	<0.001

Zip Code-Level Characteristics								
Social Vulnerability Index								
Low	1 (REF)	_	1 (REF)	_	1 (REF)		1 (REF)	
Medium	0.87 (0.87-0.87)	<0.001	0.92 (0.91-0.92)	<0.001	0.77 (0.77-0.77)	<0.001	0.83 (0.82-0.83)	<0.001
High	0.80 (0.80-0.81)		0.88 (0.88-0.89)		0.59 (0.58-0.59)		0.69 (0.68-0.69)	
Total Population, per 10,000 increase	1.04 (1.04-1.04)	<0.001	1.02 (1.02-1.02)	<0.001	1.06 (1.05-1.06)	<0.001	1.02 (1.02-1.02)	<0.001
Percent Black, per 10% increase	0.98 (0.98-0.98)	<0.001	*	*	0.95 (0.95-0.95)	<0.001	*	*
Median Income, per \$15,000 increase	1.05 (1.05-1.05)	<0.001	*	*	1.11 (1.11-1.11)	<0.001	*	*
Percent Below Poverty Line, per 2.5% increase	0.97 (0.97-0.97)	<0.001	*	*	0.93 (0.93-0.93)	<0.001	*	*
Percent without health insurance, per 2.5% increase	0.96 (0.96-0.96)	<0.001	*	*	0.90 (0.90-0.90)	<0.001	*	*
Percent in Healthcare Industry, per 2.5% increase	1.02 (1.01 -1.02)	<0.001	*	*	1.04 (1.04-1.04)	<0.001	*	*
Percent in Service Industry, per 2.5% increase	0.97 (0.97-0.97)	<0.001	*	*	0.92 (0.92-0.92)	<0.001	*	*
Vaccine sites per 10,000, per 1 site increase	1.01 (1.01-1.01)	<0.001	1.01 (1.01-1.01)	<0.001	1.01 (1.01-1.01)	<0.001	1.01 (1.01-1.01)	<0.001
Cases per 100,000, per 1500 increase	1.01 (1.01-1.01)	<0.001	1.00 (1.00-1.00)	<0.001	1.01 (1.01-1.01)		0.99 (0.99-0.99)	<0.001
Deaths per 100,000, per 50 increase	1.00 (1.00-1.00)	<0.001	1.00 (1.00-1.00)	<0.001	1.00 (1.00-1.01)		1.00 (1.00-1.00)	0.14
Region								
St. Louis	1 (REF)	~0.001	1 (REF)	~0.001	1 (REF)	~0.001	1 (REF)	~0.001
Kansas City	0.92 (0.92-0.93)	<0.001	0.95 (0.95-0.96)	<0.001	0.87 (0.87-0.87)	<0.001	0.93 (0.93-0.94)	<0.001

<u>Notes</u>: Continuous variables are scaled so that a one-unit increase represents approximately half of the interquartile range for that variable. *Excluded from multivariable model due to collinearity with social vulnerability index. Abbreviations: CI=confidence interval; REF=reference value



Figure 1: Rates and Cumulative Incidence of Receiving the Primary COVID-19 Vaccination Series and Boosters by Race/Ethnicity and SVI over Time. Estimates represent 7-day moving averages derived from multiply imputed datasets. Denominators represent the total population greater than or equal to 12 years old. Low SVI indicates zip codes with SVIs less than 0.333, medium SVI indicates SVIs between 0.333 and 0.666, and high SVI indicates SVIs greater than or equal to 0.666. SVI=Social Vulnerability Index.

Primary Series



626

Figure 2: Distribution of Primary COVID-19 Vaccine Series and Boosters by Location Type over time, SVI, and race/ethnicity. Low SVI indicates zip codes with SVIs less than 0.333, medium SVI is between 0.333 and 0.666, and high SVI is greater than or equal to 0.666. Health facilities were categorized as small-, medium-, and large-volume based on whether they vaccinated less than 1000, 1000 to 10,000, or greater than

10,000 unique individuals. Other facilities included dialysis centers, home health, nursing homes, mental health/psychiatric facilities, and 625

correctional facilities. Primary series vaccines were allocated to the location where the series was completed. SVI=Social Vulnerability Index.





Figure 3: Lorenz Curves of Disparities in COVID-19 Vaccinations. This figure depicts modified Lorenz curve 629 examining disparities in COVID-19 vaccinations as of February 15, 2022. The units of analysis are zip codes 630 and they are color-coded by their SVI. The dashed line represents equitable distribution where 50% of 631 vaccinations would be conducting in zip codes accounting for either 50% of the population, cases, deaths, or 632 total social vulnerability. Lorenz curves measure disparities in the distribution of receiving 1) the primary vaccine 633 series and 2) a booster relative to the total population above 12 years old (Panels A, B), diagnosed COVID-19 634 cases (Panels C, D), deaths, (Panels E, F), and total social vulnerability (Panels G, H).



635 636 Figure 4: Temporal Trends in COVID-19 Vaccine Inequities. This figure depicts trends in the Gini

637 coefficients over time for inequities in receiving 1) the primary vaccine series (Panel A) and 2) a booster (Panel

638 B) relative to population, diagnosed COVID-19 cases, COVID-19 deaths, and population-level social

639 vulnerability. Gini coefficients were calculated on a weekly basis from Lorenz curves generated up through that 640 time interval.





This figure depicts vaccination rates for the primary series and boosters for Black (Panel A,B), Hispanic (C, D), and Asian (E,F) residents compared to the White residents of the same zip code. Each marker represents a single zip code. Markers are color-coded by the zip code SVI and sized by the total number of vaccines administered in the zip code. The dashed line represents equitable vaccine distribution between racial/communities being compared. Zip codes falling above the dashed line indicates that there was

649 decreased vaccination in Black, Hispanic, or Asian residents as opposed to White residents (and vice versa).



Fig 1









E)





Fig 5



Fig 3

Primary Series

Booster



Small Volume Health Facility

Fig 2

Medium Volume Health Facility Large Volume Health Facility Health Department

Employer/School

Pharmacy

Other